The flu is spreading fast.
It’s killing more Canadians than ever before, and the flu shot is among the most effective, reliable, and affordable vaccines available.
But, as with everything else in the vaccine business, you can’t rely on the flu to guarantee your coverage.
You need a reliable flu shot.
And you need one that’s made from a good quality vaccine.
And, as we have previously reported, this year, the only company that is getting these kinds of vaccines is Swiss Health, which is working on a vaccine specifically for the flu.
And if you think that Swiss Health’s flu vaccine is just fine, you’re in for a shock.
A flu shot can cause serious side effects and a few of the shots can cause severe side effects as well.
For example, the flu vaccine that SwissHealth is using to vaccinate patients against the flu has been linked to a rash on two of its patients, including a 19-year-old woman who was rushed to hospital and treated for anaphylaxis.
The vaccine contains a mixture of proteins and bacteria, so it’s not perfect, but it’s close.
In the case of this woman, it did not appear that she had a rash, and a second patient had a similar rash that was treated in the same way.
But the third patient had the flu, so Swiss Health sent her home with a second flu shot, which was supposed to be given after the third shot.
Swiss Health was warned that this second vaccine could cause side effects.
And it did, according to the CBC News story.
The third patient also developed flu-like symptoms and had to go to hospital for an emergency operation.
The fourth patient, meanwhile, received the flu jab but was also warned that it could cause severe flu-related side effects including cough and fever.
Both of these patients had received Swiss Health-manufactured flu vaccines in the past.
But these vaccines were not made to be used together, so there were some concerns that they might be misused.
So, in early March, the Canadian Food Inspection Agency (CFIA) and Health Canada (HSC) warned Swiss Health that the second vaccine that it was using to make the flu vaccination might not be safe to use together with the first one.
That is, they wanted the vaccine to be tested on a larger number of people before it was sent out to the public.
The second flu vaccine made by Swiss Health is a strain that is produced in the United States and is called RVP-8.
This strain was tested by the CFIA and HSC and found to be safe.
And in a statement issued in mid-March, Swiss Health said that it is continuing to test the second flu dose, and it will send the results out to all of its vaccine manufacturers, and that they will be “conducting a thorough review of all the data, including the safety and efficacy of this vaccine and our processes and processes.”
That is a very positive sign for the influenza vaccine.
But in its statement, SwissHealth didn’t provide the full list of potential risks that it’s already seeing, such as vaccine-induced pneumonia, which it’s warning could occur when the vaccine is administered to people who are already experiencing symptoms of flu, or serious allergic reactions.
As it turns out, the third vaccine that was sent to Swiss Health did not contain the same strain of RVP that was tested, but the HSC also did not test this vaccine in the first vaccine it made.
The HSC said that because it had already been made in Canada, the two vaccines are identical.
But Swiss Health also made an error in the formulation of this flu vaccine.
It didn’t use the correct formulation of the influenza virus for the first flu shot that it sent to Switzerland.
That’s because, at the time, the virus was too small to be fully neutralized in the body.
This is one of the reasons why a vaccine is so important.
When you make a vaccine, you have to be sure that you’re making a vaccine that’s safe for the body, that it doesn’t contain a strain of the virus that is too small.
So it’s a bit of a surprise to SwissHealth that it made an oversight, when it has been in the market for more than two decades, and so is already familiar with flu vaccine safety.
But it’s also not a surprise for others, such an allergy expert who has studied flu vaccines.
Dr. David Mancuso is a professor of allergy medicine and immunology at the University of Ottawa and a member of the American Academy of Allergy, Asthma, and Immunology (AAAI) Advisory Board.
In his new book, Vaccine Safety and Immunogenicity, Mancoso discusses the dangers of combining a flu shot with a shot that contains a vaccine for a specific virus.
He says that there is a risk that the vaccine made from the second Swiss Health vaccine might contain some of the same virus as the first,